Nuveen’s Adamas Pharmaceuticals ADMS Stock Holding History

Nuveen’s Portfolio ADMS Stock Details ADMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-369,025	Closed	-$945K	–	3355
2020 Q2	$945K	Sell	369,025 -111,112	-23%	-$327K	﹤0.01%	2641
2020 Q1	$1.39M	Buy	480,137 +26,075	+6%	+$117K	﹤0.01%	2366
2019 Q4	$1.72M	Buy	454,062 +242,583	+115%	+$1.16M	﹤0.01%	2485
2019 Q3	$1.08M	Buy	211,479 +107,456	+103%	+$663K	﹤0.01%	2668
2019 Q2	$645K	Buy	+104,023	New	+$598K	﹤0.01%	2919

Other funds holding ADMS

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Nuveen's ADMS Position: Q3 2020 in Review

Nuveen sold out of Adamas Pharmaceuticals (ADMS) in Q3 2020, closing a stake of 369,025 shares — an estimated $945K sold.

Nuveen first reported a position in ADMS in Q2 2019 and held it in 5 quarters. The position peaked at $1.72M in Q4 2019. 63 funds tracked by Wall St. Rank hold ADMS as of Q3 2020.

Nuveen reported no remaining Adamas Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Nuveen sold 369,025 Adamas Pharmaceuticals shares in Q3 2020, an estimated $945K.
Nuveen first reported a position in Adamas Pharmaceuticals in Q2 2019 and held it in 5 quarters.
Nuveen's Adamas Pharmaceuticals position peaked at $1.72M in Q4 2019.
63 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q3 2020.

Based on Nuveen's 13F filing for Q3 2020, filed 16 Nov 2020.